查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433604

大麻药品市场规模、份额、趋势分析报告：按品牌类型、地区、细分市场预测，2024-2030 年

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

大麻药品市场成长与趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球大麻药品市场预计将达到 115.3 亿美元。

预计2024年至2030年该市场将以32.6%的复合年增长率扩张。大麻越来越多地用于治疗睡眠障碍、疼痛、发炎、癫痫、思觉失调症各种适应症，正在推动市场成长。对用于医疗目的的加工、量化和包装大麻产品的需求正在显着增加。此外，消费者和监管机构对大麻产品的接受程度正在提高，这对市场成长产生了积极影响。例如，监管机构对 Epidiolex 和 Sativex 等大麻产品的核准正在改善患者和医生对大麻使用的观点。

不断增加的研发活动和产品核可预计将在预测期内推动市场成长。例如，2021年8月，GW Pharmaceuticals获得英国药品和保健品监管局（MHRA）的核准，使用EPIDYOLEX治疗结节性硬化症发作。据估计，此类核准将增加製药业对大麻的需求。

越来越多的临床试验证明利用大麻药物治疗多发性硬化症、癫痫、慢性疼痛和癌症等各种疾病的积极作用正在推动市场的成长，这是主要的驱动因素。临床试验产生的积极结果可以帮助改变患者和医疗保健专业人员看待大麻和使用大麻开发的药物的方式。例如，根据 ClinicalTrials.gov 提供的资料，截至 2022 年，约有 722 项 Sativex 试验正在进行中，或正在招募、不再招募或透过邀请入组。

大麻药品市场报告亮点

  • 以品牌类型划分， 磊晶细分市场在2023年占据全球市场最大的销售份额，达98.5%。该领域的成长得益于各国核准用于治疗严重癫痫、Dravet 症候群、 肠漏症候群和结节性硬化症的进展。
  • 由于医用大麻使用者数量不断增加以及该地区主要製造商的存在，欧洲在 2023 年占据了最大的收益占有率。
  • 预计拉丁美洲市场在预测期内将以最快的速度成长。这是由于该地区大麻药物合法化的扩大和使用大麻药物的有利指导方针。

目录

第一章 大麻药品市场：调查方法与范围

第二章大麻药品市场：执行摘要

  • 市场展望
  • 分部展望
  • 竞争考察

第三章 大麻药品市场：变数、趋势、范围

  • 市场体系展望
  • 市场动态
  • 大麻药品市场分析工具

第四章 大麻药品市场：依品牌类型的估计和趋势分析

  • 依品牌类型分類的市场占有率(2023/2030)
  • 细分仪表板
  • 按品牌类型分類的市场前景
  • 市场规模、预测与趋势分析（2018-2030）

第五章 大麻药品市场：按地区估计和趋势分析

  • 按地区分類的市场占有率分析（2023/2030）
  • 按地区分類的市场仪表板
  • 按地区分類的市场概况
  • 市场规模、预测与趋势分析（2018-2030）
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 瑞士
    • 捷克共和国
    • 克罗埃西亚
    • 波兰
    • 荷兰
  • 亚太地区
    • 日本
    • 澳洲
    • 韩国
    • 纽西兰
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 乌拉圭
    • 智利
    • 秘鲁
  • 中东/非洲
    • 以色列

第六章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • Jazz Pharmaceuticals, Inc.
    • AbbVie, Inc.
    • Insys Therapeutics, Inc.
    • Bausch Health Companies, Inc.
Product Code: GVR-4-68038-473-4

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceutical market size is expected to reach USD 11.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 32.6% from 2024 to 2030.The rise in applications of cannabis for various indications, including sleep disorders, pain, inflammation, epilepsy, anorexia, multiple sclerosis, and schizophrenia, is driving the market growth. Demand for processed, quantified, and packaged cannabis products for medical purposes is significantly increasing. Moreover, consumer and regulatory acceptance of cannabis products is increasing, positively impacting the market growth. For instance, regulatory approval of cannabis-based products such as Epidiolex and Sativex is improving the perspectives of both patients and physicians regarding the use of cannabis.

An increasing number of research and development activities and product approvals are anticipated to drive market growth over the forecast period. For instance, in August 2021, GW Pharmaceutical received approval for using EPIDYOLEX to treat tuberous sclerosis complex seizures from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Such approvals are estimated to increase demand for cannabis in the pharmaceutical industry.

The rising number of clinical trials signifying the positive effects of utilizing cannabis pharmaceuticals for treating various medical conditions, such as multiple sclerosis, epilepsy, chronic pain, and cancer, is a major factor boosting market growth. Positive results provided by clinical trials help to change the perspective of patients & healthcare professionals toward cannabis and pharmaceutical drugs developed using cannabis. For instance, as per the data provided by ClinicalTrials.gov, as of 2022, there are around 722 studies for Sativex that are active, either recruiting, not recruiting, or enrolling by invitation.

Cannabis Pharmaceuticals Market Report Highlights:

  • By brand type, epidiolex segment held the largest revenue share of 98.5% in the global market in 2023. Growing approval of the drug for the treatment of severe forms of epilepsy, Dravet syndrome, Lennox Gastaut syndrome, and Tuberous Sclerosis Complex in various countries is supporting segment growth
  • Europe accounted for the largest revenue share in 2023, owing to growing number of medical cannabis users, along with the presence of major manufacturers in the region
  • Latin American markets are estimated to grow at the fastest rate during the forecast period. This can be attributed to growing legalization and favorable guidelines toward using cannabis pharmaceuticals in the region

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework
      • 5.5.1.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework
      • 5.5.2.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework
      • 5.6.1.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework
      • 5.6.2.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework
      • 5.6.3.3. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Italy
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework
      • 5.6.4.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Switzerland
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework
      • 5.6.5.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Czech Republic
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework
      • 5.6.6.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework
      • 5.6.7.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework
      • 5.6.8.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Netherlands
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework
      • 5.6.9.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework
      • 5.7.1.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework
      • 5.7.2.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. South Korea
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework
      • 5.7.3.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. New Zealand
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework
      • 5.7.4.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework
      • 5.8.1.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework
      • 5.8.2.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework
      • 5.8.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework
      • 5.8.4.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework
      • 5.8.5.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework
      • 5.8.6.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework
      • 5.8.7.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. Israel
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework
      • 5.9.1.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Jazz Pharmaceuticals, Inc.
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. AbbVie, Inc.
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. Insys Therapeutics, Inc.
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. Bausch Health Companies, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Netherland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 19 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 Latin America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 25 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 MEA cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 34 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Cannabis pharmaceuticals market driver impact
  • Fig. 13 Cannabis pharmaceuticals market restraint impact
  • Fig. 14 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 15 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 16 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 17 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 18 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 19 Global cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 20 Global cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 21 North America, by country
  • Fig. 22 North America market estimates and forecasts, 2018 - 2030
  • Fig. 23 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 24 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 25 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 26 UK market estimates and forecasts, 2018 - 2030
  • Fig. 27 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 28 France market estimates and forecasts, 2018 - 2030
  • Fig. 29 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 30 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 31 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 32 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 33 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 34 Netherland market estimates and forecasts, 2018 - 2030
  • Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 36 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 37 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 38 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 39 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 40 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 41 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 43 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 44 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 45 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 46 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 47 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 48 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 49 Israel market estimates and forecasts, 2018 - 2030